MT-2301 Hib vaccine candidate shows efficacy in phase 2 study of 154 infants

This completed phase 2 study, sponsored by Tanabe Pharma Corporation, aimed to evaluate the efficacy and safety of the investigational vaccine MT-2301 when co-administered with DPT-IPV in healthy infants, using ActHIB as a control. The study condition was Haemophilus Influenza Type b. The intervention arms included Haemophilus b conjugate vaccine (diphtheria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine (diphtheria CRM197 protein conjugate)-High + DPT-IPV, and Haemophilus influenza type b conjugate vaccine + DPT-IPV, all classified as biological interventions. The control was ActHIB. The study enrolled 154 participants. The primary outcome measure was the antibody prevalence rate against anti-PRP with 1 μg/mL or higher, defined as the percentage of participants with the antibody against anti-PRP. The study started in April 2014, with primary completion in January 2015. Results were posted on September 19, 2024. The abstract does not provide specific numerical results for the primary efficacy outcome, safety data, or comparative statistics between the intervention and control groups. Therefore, no efficacy rates, p-values, confidence intervals, or specific safety signals can be reported from the provided abstract text. The study design was an exploratory clinical study comparing the candidate vaccine MT-2301 at different dose levels against an active control.

When your baby gets their routine shots, you want to know they're getting the best possible protection. This study looked at a new candidate vaccine for Haemophilus influenzae type b (Hib), a bacteria that can cause serious infections like meningitis in young children. The researchers wanted to see how well this new vaccine worked and how safe it was when given at the same time as the standard DPT (diphtheria, pertussis, tetanus) and polio vaccines.

They compared the new vaccine, called MT-2301, given at two different dose levels, to an already approved Hib vaccine (ActHIB®). All vaccines were given alongside the DPT-polio shot to 154 healthy infants. The main goal was to see what percentage of babies developed a level of protective antibodies against the Hib bacteria that is considered effective. The study also tracked safety.

The abstract reports the study is completed, but it does not share the specific results for antibody levels or safety findings. Without those numbers, we don't know if the new vaccine candidate performed better, the same, or worse than the existing vaccine. The completion of this phase 2 trial is a necessary step to gather that crucial data, which helps determine if the new vaccine should move forward in development for potential future use.